(News Bulletin 247) – GSK advises that the Advisory Committee on Immunization Practices (ACIP) of the United States Centers for Disease Control and Prevention (CDC) has declared itself in favor of the use of Arexvy (the vaccine against respiratory syncytial virus – RSV – with adjuvant) in adults aged 60 years in the context of shared clinical decision-making.
GSK says shared clinical decision-making allows patients, in consultation with their healthcare professionals, to determine whether RSV vaccination is right for them.
The company said it was ‘grateful’ to ACIP and the CDC for recognizing the potential of Arexvy and expressed its eagerness to partner with various public health officials and professionals to put its vaccine available to the elderly before the start of the RSV season.
ACIP’s recommendations will be forwarded to the CDC Director and the US Department of Health and Human Services for review and approval. Once approved, the final recommendations will be published in a future Morbidity and Mortality Weekly Report (MMWR) to advise healthcare providers on the appropriate use of the vaccine.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
